^
CD276 overexpression
Triple Negative Breast Cancer
B7H3-targeted CAR-T immunotherapy
Sensitive
:
D
ASGCT 2021 - 1wk
No biomarker
Triple Negative Breast Cancer
sacituzumab govitecan-hziy
Sensitive
:
A1
N Engl J Med - 2wk
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive
:
A1
AACR 2021 - 3wk
RB1 negative
Triple Negative Breast Cancer
VRN08
Sensitive
:
D
AACR 2021 - 3wk
PD-L1 expression
Triple Negative Breast Cancer
pembrolizumab
Sensitive
:
A1
No biomarker
Triple Negative Breast Cancer
CaT
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
cisplatin
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
cisplatin
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
carboplatin
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
carboplatin
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
gemcitabine
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
gemcitabine
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
capecitabine
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
capecitabine
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
vinorelbine tartrate
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
vinorelbine tartrate
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
eribulin mesylate
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
eribulin mesylate
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
pegylated liposomal doxorubicin
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
pegylated liposomal doxorubicin
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
paclitaxel
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
olaparib
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
olaparib
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
talazoparib
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
talazoparib
Sensitive
:
A2
No biomarker
Triple Negative Breast Cancer
carboplatin
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
doxorubicin hydrochloride
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
doxorubicin hydrochloride
Sensitive
:
A2
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our